Clinical Trial Update: Treatment of Patients With Anxiety Disorder (0777-022) [Phase 2]

View source ↗

Summary

Phase 2 trial for Generalized Anxiety Disorder sponsored by Merck Sharp & Dohme LLC has completed. The update does not include efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED